[Comparative results of therapy with amizon and reaferon of patients with chronic viral hepatitis B and C and kidney complications].
A comparative clinical-and-laboratory investigation was undertaken designed to study efficiency of employment of reaferon and amison in 30 patients with viral hepatitis B and 30 patients with viral hepatitis C and renal lesions. Amison has been shown to significantly reduce or dispel dispeptic events in the above patient populations, with no serious ill effects noted. Amison has proved to be endowed with the ability to exert apparent antiinflammatory, interferonogenic, immunomodulating, and hepatoprotecting effects, and it is much cheaper compared to reaferon.
Kominko
L V
LV
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D016174:Hepacivirus / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007674:Kidney Diseases / Q000209:etiology*; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011726:Pyridinium Compounds; D011994:Recombinant Proteins; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011725:Pyridines; D011726:Pyridinium Compounds; D011994:Recombinant Proteins; C410106:enisamium